DYNLL1, dynein light chain LC8-type 1, 8655

N. diseases: 103; N. variants: 5
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker disease BEFREE We are interested in understanding the inhibitory mechanism of metformin on tumor-associated inflammation in prostate cancer.<b>Experimental Design:</b> By using a transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse model, <i>in vitro</i> macrophage migration assays, and patient samples, we examined the effect of metformin on tumor-associated inflammation during the initiation and after androgen deprivation therapy of prostate cancer.<b>Results:</b> Treating TRAMP mice with metformin delays prostate cancer progression from low-grade prostatic intraepithelial neoplasia to high-grade PIN, undifferentiated to well-differentiated, and PIN to adenocarcinoma with concurrent inhibition of inflammatory infiltration evidenced by reduced recruitment of macrophages. 30012567 2018
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker disease BEFREE The prostate-specific G-protein coupled receptor (PSGR, or OR51E2) is an olfactory receptor family member with highly specific expression in human prostate epithelium that is highly overexpressed in PIN and prostate cancer. 27280498 2016
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker disease BEFREE No association was found for correlation of PCA3 score change with age >65 years (p=0.975), family history of prostate cancer (p=0.796), positive DRE (p=0.179), use of 5-alpha-reductase inhibitors (p=0.793) and BPH/prostatitis/HG-PIN/ASAP diagnosis (p=0.428). 25862908 2015
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 AlteredExpression disease BEFREE In the present communication, we found increased LIV-1 expression in benign, PIN, primary and bone metastatic human prostate cancer. 22110740 2011
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker disease BEFREE Strong immunostaining for CRISP-3 is common in HG-PIN and preserved in most PCa specimens, which warrant further immunohistochemical studies of CRISP-3 in PCa. 16388501 2006
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker disease BEFREE Statistically significant differential SCD expression between normal and cancerous epithelium was determined at the p=0.001 level, and between PIN and prostate carcinoma at the p=0.03 level. 15609334 2005
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker disease BEFREE Prolonged treatment of adult rodents with estrogens along with androgens also leads to epithelial metaplasia, PIN-like lesions and even adenocarcinoma of prostate speaking for the role of estrogen in prostate cancer development. 15663993 2004
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker disease BEFREE This group of high-risk patients includes men with a family history of prostate cancer and various histologic features such as PIN and ASAP identified on an initial biopsy. 14680306 2003
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 AlteredExpression disease BEFREE We shortlist and discuss the most significant over-expressed genes in prostate cancer and PIN, and highlight expression differences between malignant and benign samples. 11384102 2001
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma
0.100 Biomarker disease BEFREE The clinical importance of recognizing PIN is based on its strong association with prostatic carcinoma. 8700801 1996